Study S000879

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06565611
Acronym: BMT-801
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 108
Start: 2024-08-05
Primary completion: 2025-02-05
Lead sponsor: Palatin Technologies, Inc
Conditions: Obesity
Interventions: DRUG:bremelanotide; DRUG:tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent change in body weight between treatment arms [Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.